Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to 24.55%.

  • Dna X's EBITDA Margin fell 87300.0% to 24.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.43%, marking a year-over-year decrease of 318900.0%. This contributed to the annual value of 57.7% for FY2024, which is 582500.0% down from last year.
  • Latest data reveals that Dna X reported EBITDA Margin of 24.55% as of Q3 2025, which was down 87300.0% from 60.16% recorded in Q2 2025.
  • Over the past 5 years, Dna X's EBITDA Margin peaked at 3.86% during Q1 2025, and registered a low of 147.52% during Q4 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 24.55% (2025), whereas its average is 36.73%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 693100bps in 2022, then tumbled by -1381700bps in 2024.
  • Dna X's EBITDA Margin (Quarter) stood at 73.71% in 2021, then soared by 94bps to 4.39% in 2022, then tumbled by -113bps to 9.34% in 2023, then crashed by -1479bps to 147.52% in 2024, then soared by 83bps to 24.55% in 2025.
  • Its EBITDA Margin stands at 24.55% for Q3 2025, versus 60.16% for Q2 2025 and 3.86% for Q1 2025.